Outlook Therapeutics, Inc. (OTLK) is gearing up for a series of key catalysts over the coming months that could significantly impact the company's trajectory, especially regarding its lead product, LYTENAVA.LYTENAVA is an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration or wet AMD. The company received Marketing Authorization for LYTENAVA in the Europ...
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.